Recombinant Human ADAM8 Protein (HEK293)，Avi & His

ADAM8, a member of the ADAM (A Disintegrin and Metalloproteinase) family, is a type I transmembrane protein characterized by its structure that includes a pro-domain, a metalloproteinase domain, a disintegrin domain, a cysteine-rich domain, and an epidermal growth factor-like domain. Research has highlighted ADAM8's significant role in various biological processes, including cell adhesion, migration, and signaling, particularly in the context of inflammation, cancer progression, and tissue remodeling. Elevated levels of ADAM8 have been associated with several pathological conditions, such as asthma, rheumatoid arthritis, and tumors, where it contributes to the cleavage of various substrates, affecting the tumor microenvironment and immune responses. The ability of ADAM8 to modulate these processes makes it a potential therapeutic target, warranting its recombinant protein production for studying its function and the underlying mechanisms involved. By utilizing recombinant DNA technology, researchers aim to produce ADAM8 in a controlled environment, enabling detailed analysis of its enzymatic activity, binding capabilities, and its interactions with other cellular components. This research not only elucidates the role of ADAM8 in health and disease but also paves the way for developing targeted inhibitors that could provide novel treatment options for ADAM8-related disorders. Understanding the structure-function relationship of ADAM8 through recombinant studies may lead to significant advancements in medical research, particularly in the fields of oncology and immunology.